 |
|
Improved predictive value of biomarkers in HF makes earlier diagnosis and better management possible
March 30, 2009With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease. Yet despite improvements in its diagnosis and management, heart failure remains a stubbornly incurable condition with a poor prognosis, largely amenable to little more than palliative therapy.
Heart failure describes a syndrome of symptoms without a single diagnostic test. However, the discovery and application of markers of disease (biomarkers) have improved risk stratification in heart failure and made earlier detection possible. Now, reports in the April issue of the European Journal of Heart Failure suggest two more efficient applications of biomarkers, and with them the promise of even earlier diagnosis and improved treatment.
1. According to results from a study in Hull, UK, repeat measurement of the well established biomarker N-terminal pro-B-type natriuretic peptide (NT-proBNP) once treatment has been optimised provides stronger prognostic information than either the baseline value, the change in NT-proBNP, or other conventional methods of assessment. (1)
The finding emerged from a study of 354 patients with chronic heart failure treated in a community-based heart failure programme. Measurement of (NT-proBNP) was performed at baseline and, in those surviving (318), once again between the fourth and sixth month of follow-up. During the study follow-up period (a median of 39 months) 125 patients died, and analysis showed that follow-up NT-proBNP measurement proved a better predictor of death than either baseline NT-proBNP or change in NT-proBNP. Indeed, say the authors, NT-proBNP "was consistently the strongest independent prognostic marker at predicting death or unplanned cardiovascular hospitalisations after baseline or follow-up assessment".
First author Dr Milos Kubanek from Castle Hill Hospital, Hull, UK, added: "NT-proBNP monitoring will enable the identification of patients who are not responding well to treatment or help flag those patients needing more aggressive management and monitoring. We found NT-proBNP to be a much stronger predictor of mortality and CV-hospitalisation than echocardiographic measurements of, for example, ejection fraction, and therefore repeat NT-proBNP measurement may enable a reduction in the number of repeat echocardiograms.
"We suggest that the main role of conventional echocardiography should be to diagnose and differentiate the principal causes of heart failure, with subsequent NT-proBNP monitoring used to identify worsening disease and trigger further echocardiographic assessment. Given the relatively high cost of echocardiography compared to NT-proBNP, such a policy is likely to be cost effective."
2. A study from Sweden suggests the combined application of two independently established biomarkers gives better prognostic information about the risk of cardiovascular mortality in heart failure patients than just one biomarker.(2) This was a study of 464 elderly patients with the symptoms of heart failure followed up over a ten-year period Linkoping University Hospital. Throughout that time serum measurements of the biomarker cystatin C (a marker of renal function) were taken, with results showing that those with levels within the highest quartile had almost three times the risk of cardiovascular death than those with levels in the first, second, or third quartiles.
However, when these measurements were combined with measurements of NT-proBNP, the mortality risk assessment was even more emphatic. For example, if those with high concentrations of cystatin C also had a plasma concentration of NT-proBNP within the highest quartile, the risk of death increased to more than 13 times over ten years of follow-up and almost 17 times after five years of follow-up.
The study's first author, Dr Urban Alehagen from the Heart Center of Linkoping University Hospital, Linkoping, Sweden, said: "Because the majority of patients with heart failure are elderly and often affected by other organ symptoms, including renal impairment, it is important to identify those at high risk, both for the provision of optimal treatment and the most effective use of health resources. The use of a single blood test and the analysis of two biomarkers is one way of identifying those patients where health resources are best focused. More and more clinicians are using information from natriuretic peptides. However, it is now possible to expand the use of these biomarkers in clinical practice, and our study proposes one such potent combination."
The use of biomarkers for identifying those at risk of cardiovascular mortality is now central to the management of patients with heart failure. Research now aims to find new, more sensitive markers and more efficient use of existing markers. The ultimate aim, as this issue of the European Journal of Heart Failure suggests, is to make earlier and more accurate diagnosis possible, and thereby improve treatment and survival.
Commenting on the implications of the findings, Professor Karl Swedberg, Editor-in-Chief of the European Journal of Heart Failure, said: "A combination of biomarkers to improve diagnosis and prognosis - as suggested by Alehagen and colleagues - now seems to be the basis of optimal management of patients with heart failure."
European Society of Cardiology
The finding emerged from a study of 354 patients with chronic heart failure treated in a community-based heart failure programme. Measurement of (NT-proBNP) was performed at baseline and, in those surviving (318), once again between the fourth and sixth month of follow-up. During the study follow-up period (a median of 39 months) 125 patients died, and analysis showed that follow-up NT-proBNP measurement proved a better predictor of death than either baseline NT-proBNP or change in NT-proBNP. Indeed, say the authors, NT-proBNP "was consistently the strongest independent prognostic marker at predicting death or unplanned cardiovascular hospitalisations after baseline or follow-up assessment".
First author Dr Milos Kubanek from Castle Hill Hospital, Hull, UK, added: "NT-proBNP monitoring will enable the identification of patients who are not responding well to treatment or help flag those patients needing more aggressive management and monitoring. We found NT-proBNP to be a much stronger predictor of mortality and CV-hospitalisation than echocardiographic measurements of, for example, ejection fraction, and therefore repeat NT-proBNP measurement may enable a reduction in the number of repeat echocardiograms.
"We suggest that the main role of conventional echocardiography should be to diagnose and differentiate the principal causes of heart failure, with subsequent NT-proBNP monitoring used to identify worsening disease and trigger further echocardiographic assessment. Given the relatively high cost of echocardiography compared to NT-proBNP, such a policy is likely to be cost effective."
2. A study from Sweden suggests the combined application of two independently established biomarkers gives better prognostic information about the risk of cardiovascular mortality in heart failure patients than just one biomarker.(2) This was a study of 464 elderly patients with the symptoms of heart failure followed up over a ten-year period Linkoping University Hospital. Throughout that time serum measurements of the biomarker cystatin C (a marker of renal function) were taken, with results showing that those with levels within the highest quartile had almost three times the risk of cardiovascular death than those with levels in the first, second, or third quartiles.
However, when these measurements were combined with measurements of NT-proBNP, the mortality risk assessment was even more emphatic. For example, if those with high concentrations of cystatin C also had a plasma concentration of NT-proBNP within the highest quartile, the risk of death increased to more than 13 times over ten years of follow-up and almost 17 times after five years of follow-up.
The study's first author, Dr Urban Alehagen from the Heart Center of Linkoping University Hospital, Linkoping, Sweden, said: "Because the majority of patients with heart failure are elderly and often affected by other organ symptoms, including renal impairment, it is important to identify those at high risk, both for the provision of optimal treatment and the most effective use of health resources. The use of a single blood test and the analysis of two biomarkers is one way of identifying those patients where health resources are best focused. More and more clinicians are using information from natriuretic peptides. However, it is now possible to expand the use of these biomarkers in clinical practice, and our study proposes one such potent combination."
The use of biomarkers for identifying those at risk of cardiovascular mortality is now central to the management of patients with heart failure. Research now aims to find new, more sensitive markers and more efficient use of existing markers. The ultimate aim, as this issue of the European Journal of Heart Failure suggests, is to make earlier and more accurate diagnosis possible, and thereby improve treatment and survival.
Commenting on the implications of the findings, Professor Karl Swedberg, Editor-in-Chief of the European Journal of Heart Failure, said: "A combination of biomarkers to improve diagnosis and prognosis - as suggested by Alehagen and colleagues - now seems to be the basis of optimal management of patients with heart failure."
European Society of Cardiology
Heart Failure Current Events and Heart Failure News RSSResearchers develop innovative imaging system to study sudden cardiac arrest
A research team at Vanderbilt University has developed an innovative optical system to simultaneously image electrical activity and metabolic properties in the same region of a heart, to study the complex mechanisms that lead to sudden cardiac arrest.
Experts unveil new CVD guidelines and position papers
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
UT Southwestern patient first in North Texas to receive newest-generation heart failure device
UT Southwestern Medical Center patient Michael LeBlanc, 40, is the first in North Texas to receive the newest generation of a mechanical device designed to improve heart function. It will be his lifeline while he awaits a heart transplant.
Learning the risks for stroke - and taking action
With this theme in mind, the European Society of Cardiology (ESC) emphasises that most of the risks for stroke are also the major risks for coronary heart disease - and thus the object of the ESC's far-reaching prevention programme.
Concurrent imaging of metabolic and electric signals in the heart
Cardiac rhythm disorders can result from disturbances in cardiac metabolism. These metabolic changes are tightly linked with specific cardiac electrophysiology (CEP) abnormalities, such as depressed excitability, impaired intra- and extracellular conductivities, wave propagation block, and alteration of conduction velocity, action potential amplitude, and duration.
Canadian cardiology team clears the way for lifesaving breast cancer treatment
A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
'Superobesity,' chronic disease burden associated with risk of death following bariatric surgery
Veterans classified as superobese and those with a higher chronic disease burden appear more likely to die within a year of having bariatric surgery, according to a report in the October issue of Archives of Surgery, one of the JAMA/Archives journals.
Thyroid surgery safe for older patients, study finds
Thyroid surgery is safe for older patients, say physicians who found only slight differences in rates of complications and hospital readmissions in a multi-year study.
New mathematical model more accurately diagnoses acute heart failure in emergency rooms
Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients.
Cost Effectiveness of Blood Pressure Device Evaluated
A study conducted by the University of Rochester Medical Center (URMC) demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension.
More Heart Failure Current Events and Heart Failure News Articles
 |
Success with Heart Failure (mass mkt ed): Help and Hope for Those with Congestive Heart Failure by Marc Silver (Author) Up-to-date information on available and forthcoming medical and surgical treatments. How attitude and emotion affect heart failure--and what you can do to stay positive. Tips for adopting a heart-healthy diet and lifestyle. Ways to forge a positive working relationship with your doctor or cardiologist. |
 |
The Cleveland Clinic Guide to Heart Failure (Cleveland Clinic Guides) by Randall Starling (Author) Expert medical advice from the #1 heart center in America for 14 years in a row
For the 5 million people with heart failure, there’s new reason for hope: recent medical advances have revolutionized how this condition is managed.
In The Cleveland Clinic Guide to Heart Failure, Dr. Randall Starling, one of the foremost authorities on heart health, provides authoritative advice to help people survive heart failure and enjoy a good quality of life. This comprehensive resource gives readers the cutting-edge medical guidance Dr. Starling offers his patients, including:
* Insight into what causes heart failure * The latest breakthrough studies – and what those discoveries mean for the future of this disease * Reliable guidance on diagnostic tests and treatment... |
 |
Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (HEART FAILURE: PATHOPHYSIOLOGY, MOLEC BIOL & CLIN MGT) by Arnold M Katz (Author), Marvin A Konstam (Author) This Second Edition of Dr. Katz's highly acclaimed text has been thoroughly revised to incorporate the latest advances in the study and treatment of heart failure. The book explains the pathophysiology, molecular mechanisms, clinical manifestations, and therapy of heart failure in an integrated, reader-friendly manner that is accessible to both clinicians and basic scientists. More than 100 illustrations, most created for this book by the authors, complement the text. This edition has been completely reorganized. Chapters describe the hemodynamic basis for the clinical manifestations of heart failure; the neurohumoral responses in heart failure and key signaling pathways that mediate functional responses; the proliferative responses in failing hearts; the cellular and molecular... |
 |
Heart Failure Cruel Hand (Primary Contributor) |
 |
FlameEz-Heart, 60 Capsules/Bottle by FlameEz Conditions that damage the heart muscle or make it work too hard can cause heart failure. Over time, the heart weakens and certain inflammatory substances may be released into the blood, which have a toxic effect on the heart and cause heart failure to worsen. The most common causes of heart failure are coronary artery disease, high blood pressure, and diabetes, all of which are associated with chronic inflammation. Inflammatory cytokines suppress heart contractility, initiate hypertrophy and promote cell death or fibrosis. Results from a recent study land additional support that obesity causes prolonged inflammation of heart tissue that in turn boosts heart failure risk. New studies also suggest that modulation of inflammatory and immune responses may offer some hope to improve heart... |
 |
Heart Failure Heart failure, also called congestive heart failure, is a condition in which the heart cannot pump enough oxygenated blood to meet the needs of the body?s other organs. The heart keeps pumping, but not as efficiently as a healthy heart. Usually, the loss in the heart?s pumping action is a symptom of an underlying heart problem. Heart failure affects nearly 5 million US adults. It is on the rise with an estimated 400,000 to 700,000 new cases each year. This talk will focus on the causes, symptoms, diagnosis and treatments available for heart failure, including current research findings from Stanford. |
|
Holy Heart Failure by Holy Heart Failure | |
 |
Post Heart Attack / Heart Failure Directed By: (c) Information Television Network |
|
Pathophysioloby, Volume 1: Heart Failure [VHS] Starring: Mosby | |
 |
Congestive Heart Failure Awareness Ribbon Mouse Pad by MyHeritageWear.com The Congestive Heart Failure Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Congestive Heart Failure Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Congestive Heart Failure Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
| © 2009 BrightSurf.com |